Evaluation of SD Bioline HIV/syphilis Duo rapid test kits in Nepal

Accurate and prompt diagnosis of HIV and syphilis is critical to disease control especially during the antenatal period with an additional opportunity for treatment and prevention of adverse effects of these disorders on the offspring.

Review of literature shows that co-infection with syphilis can increase the transmission of HIV by both increasing viral shedding through open ulcers [1, 2] and by increasing patient viral load [3, 4]. Simple user-friendly two-pronged and affordable detection tools could save lives and reduce overall costs borne by patients and health systems.

Rapid, accessible tests for simultaneous screening for HIV as well as syphilis are available on the market, but reliable information about their efficiency and dependability in quality or performance is coming up only gradually. Reliable evaluation reports of commercially available rapid diagnostic tests for tuberculosis [5] has been published but for syphilis and HIV large sized study reports of dual test kits are yet awaited.

Screening for HIV and syphilis is a basic routine test being an inseparable part of any antenatal check-up protocol and is also endorsed in the American Congress of Obstetricians and Gynecologists (ACOG) Guidelines for Perinatal Care [6]. Simultaneous screening for both these disorders would be cost-effective as well as time-saving. The current situation in Nepal entails the practice of testing separately for syphilis by screening by RPR test and confirmation by TPHA method and testing for HIV by following the National algorithm for HIV rapid diagnosis [7].

So, a rapid dual testing kit would meet the long felt need in the field as well as in the hospital settings. Hence, in cooperation with rapid test kit manufacturers, SD Bioline/NPHL, we undertook an evaluation of commercially available HIV/syphilis Duo rapid test kit (SD Bioline) to assess its performance, reproducibility and operational characteristics and to identify its utility as a reliable screening tool.

The study was carried out with the cases enrolled at the antenatal clinic of Paropkar Maternity and Women’s Hospital (PMWH), Kathmandu, Nepal with the test-confirmation and backup-reference laboratory testing supported by the National Public Health Laboratory, Teku, Kathmandu, Nepal during the study period between July, 2014 and December, 2014.

Paropkar Maternity and Women’s Hospital is the largest maternity and gynecological hospital of the country serving population of the local embankment area communities as well as a large number of referral cases from all over the country. The National Public Health Laboratory is the apex laboratory institution of the country serving as a general and reference laboratory especially for investigations of public health importance.

All women attending the antenatal clinic of PMWH were enrolled in the study. This included all cases on their first visit to the ANC clinic as well as those on subsequent visits or for delivery, without being previously screened for HIV and/or syphilis. Women who were diagnostically confirmed cases or those already on therapeutic intervention with presumed diagnosis fell into the exclusion criteria. Informed written consent were taken in local language from all participants and ethical approval obtained from the ethical committee of the Nepal Health Research Council (NHRC).

Sample collection: Two types of samples were collected depending upon suitability for the tests and patient convenience: [1] blood collection by venipuncture for serum collection and [2] capillary blood collection by finger-prick method. All procedures for specimen collection were performed by laboratory personnels taking all biosafety precautions.

Test kit: SD BIOLINE HIV/syphilis Duo test kits (Standard Diagnostic Inc., Korea) were obtained for the evaluation study.

Total number of samples collected were 10,000, out of which 9,453 (94.53 %) were serum samples and 547 (5.47 %) were finger-prick whole blood samples as shown in Table 1. Of the women attending the ante-natal clinic 57.71 % were already in advanced pregnancy and near to delivery.

An evaluation of the diagnostic performance of the SD BIOLINE HIV/syphilis Duo test which is a two-pronged screening kit for simultaneous detection of HIV and syphilis, has been undertaken in the present study. The sensitivity and specificity of the kit in detecting HIV infection were found to be remarkably high at 100 %. These findings reiterate the results of earlier studies done in other countries [9, 10]. Comparable results have also been reported from the Southern Ethiopia, 2014 [11] study using the same test kit (shown in Table 3).

A rapid and sensitive tool for HIV testing has been a long felt need among health workers in the fields and the hospitals. Moreover, a two-pronged test kit designed for simultaneous HIV and syphilis detection has been a pressing need in the settings of the antenatal clinics and as a screening test for prospective mothers. SD BIOLINE HIV/syphilis Duo test has displayed many merits needed for such a test. The consequences of false negative test results in HIV testing of pregnant mothers have negative impact on efforts for the prevention of mother to child transmission of HIV infection (PMTCT). So, the results of the present evaluation as a reliable screening test for HIV without false negative test result need to be interpreted from these perspectives also. However, the SD BIOLINE HIV/syphilis Duo test’s usefulness for screening HIV-infected cases missed by other tests must be emphasized. Good screening tests do not replace the confirmatory reference tests but by their performances the consequences of false negative tests could be prevented to a great extent.

In the present study, for the diagnosis of syphilis The SD BIOLINE HIV/syphilis Duo test demonstrated a sensitivity of 95.45 % (95 % CI: 84.86–98.74 %) and specificity was 99.87 % (95 % CI; 99.78–99.92 %). The positive predictive value was 76.36 % (95 % CI; 63.65–85.63 %) and negative predictive value was 99.89 % (95 % CI; 99.39–99.99 %) and Kappa value was found to be 0.85. But these results have to be interpreted in the light of the fact that the predictive value of a test depends on the prevalence of a particular infection, and that the test may also demonstrate different performance elsewhere in lower prevalence regions. However, within the constraints of limited availability of diagnostic options in many resource-limited countries the SD BIOLINE HIV/syphilis Duo test can be a strategic tool for cost effective intervention in syphilis control through antenatal screening and treatment of positive cases [12].

Simple and easy method of dual screening of HIV and syphilis as observed in case of SD BIOLINE HIV/syphilis Duo test enhances the accessibility of quality screening service for most communities of the developing countries. Besides, this presents an opportunity to be automatically tested for syphilis for all those who get HIV testing without having to wait for the results of a second test. This may be an important step towards global elimination of HIV and syphilis in the pregnant women and other vulnerable risk groups.

Both HIV and syphilis being sexually transmitted diseases share common mode of transmission because of which simultaneous screening for both reinforces the control strategy of one by the other. By using this dual test kit as a point of care testing great impact can be expected in the control of both HIV and syphilis in the economically disadvantaged communities as point of care tests are strategic tools for the control and management of STIs [13].

The performance characteristics of the SD Bioline HIV/Syphilis Duo test kit were found almost concordant with the reference kits currently being used for HIV and Syphilis diagnosis in Nepal. The performance of the kit was observed better for HIV diagnosis than for diagnosis of syphilis. Use of SD Bioline HIV/Syphilis Duo test in antenatal clinics/HTCs would meet the long felt need for a good screening tool for their day to day use with opportunity for simultaneous diagnosis of HIV and syphilis.